If NTS could regulate MUL1 or RNF126 activity at the same time, NTS will be a strong therapeutic tool for leukemia therapy compared to other drugs (e.g., Imatinib) through AKT or mTOR ubiquitination. This evidence concerns the gene RNF126 and leukemia.